{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:38:29Z","timestamp":1780468709845,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave. However, the efficacy and safety of azvudine versus Paxlovid are poorly established. This study included 40,876 hospitalized patients with COVID-19 from eleven hospitals in Henan and Xinjiang Provinces, China. Clinical outcomes were compared between the two drugs via Kaplan\u2013Meier analysis and Cox regression models. Additionally, in vitro and in vivo experiments were used to evaluate the antitumor effects and safety of both drugs. Single-cell RNA sequencing was performed to elucidate the tumor immune landscape after azvudine treatment. After propensity score matching, 2404 azvudine and 1202 Paxlovid recipients from Henan Province were included. Cox regression revealed that azvudine was related to an 18% lower risk of all-cause death than Paxlovid (95% CI: 0.676\u20130.987), was not obviously different in composite disease progression. The robustness of the findings was verified by the Xinjiang cohort and three sensitivity analyses. Fewer adverse events were observed in the azvudine group. Subgroup analysis revealed that azvudine provided greater benefits for patients with malignant tumors, significantly reducing both all-cause death (hazard ratio [HR]: 0.33, 95% CI: 0.20\u22120.54) and composite disease progression (HR: 0.54, 95% CI: 0.33\u22120.88). Furthermore, azvudine can suppress the growth of hepatocellular carcinoma (HCC) by regulating CD4<jats:sup>+<\/jats:sup> T and CD8<jats:sup>+<\/jats:sup> T cells in vivo. These findings suggest that azvudine therapy is not inferior to Paxlovid in hospitalized COVID-19 patients and has fewer adverse effects. Notably, azvudine may offer greater clinical benefit for patients with HCC.<\/jats:p>","DOI":"10.1038\/s41392-025-02126-w","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T23:03:23Z","timestamp":1737068603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real\u2010world effectiveness and safety of oral azvudine versus nirmatrelvir\u2012ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study"],"prefix":"10.1038","volume":"10","author":[{"given":"Haiyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuerganaili","family":"Aji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guotao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linqi","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanyue","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranran","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbiao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zujiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0798-3444","authenticated-orcid":false,"given":"Zhigang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"2126_CR1","unstructured":"World Health Organization. WHO COVID-19 dashboard. https:\/\/data.who.int\/dashboards\/covid19\/cases?n=c (2024)."},{"key":"2126_CR2","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2372\u20132383.e2379 (2021).","journal-title":"Cell"},{"key":"2126_CR3","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.3390\/vaccines10111944","volume":"10","author":"M Gonz\u00e1lez-Block","year":"2022","unstructured":"Gonz\u00e1lez-Block, M., Guti\u00e9rrez-Calder\u00f3n, E. & Sarti, E. COVID-19 vaccination hesitancy in Mexico City among healthy adults and adults with chronic diseases: a survey of complacency, confidence, and convenience challenges in the transition to endemic control. Vaccines 10, 1944 (2022).","journal-title":"Vaccines"},{"key":"2126_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693\u2013704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2126_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jinf.2021.03.008","volume":"82","author":"E Tharmarajah","year":"2021","unstructured":"Tharmarajah, E. et al. IL-6 inhibition in the treatment of COVID-19: a meta-analysis and meta-regression. J. Infect. 82, 178\u2013185 (2021).","journal-title":"J. Infect."},{"key":"2126_CR6","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397\u20131408 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2126_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 386, 509\u2013520 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2126_CR8","first-page":"100321","volume":"3","author":"B Yu","year":"2022","unstructured":"Yu, B. & Chang, J. The first Chinese oral anti-COVID-19 drug Azvudine launched. Innovation 3, 100321 (2022).","journal-title":"Innovation"},{"key":"2126_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa2301425","volume":"390","author":"B Cao","year":"2024","unstructured":"Cao, B. et al. Oral simnotrelvir for adult patients with mild-to-moderate Covid-19. N. Engl. J. Med. 390, 230\u2013241 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2126_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2208822","volume":"388","author":"Z Cao","year":"2023","unstructured":"Cao, Z. et al. VV116 versus nirmatrelvir-ritonavir for oral treatment of Covid-19. N. Engl. J. Med. 388, 406\u2013417 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2126_CR11","unstructured":"National Medical Products Administration. China grants conditional approval for Pfizer\u2019s oral COVID-19 drug. https:\/\/english.nmpa.gov.cn\/2022-02\/14\/c_707085.htm (2022)."},{"key":"2126_CR12","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/jac\/dkad027","volume":"78","author":"T Kuroda","year":"2023","unstructured":"Kuroda, T. et al. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo. J. Antimicrob. Chemother. 78, 946\u2013952 (2023).","journal-title":"J. Antimicrob. Chemother."},{"key":"2126_CR13","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S0140-6736(22)01586-0","volume":"400","author":"CKH Wong","year":"2022","unstructured":"Wong, C. K. H. et al. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet 400, 1213\u20131222 (2022).","journal-title":"Lancet"},{"key":"2126_CR14","first-page":"100602","volume":"30","author":"AK Wai","year":"2023","unstructured":"Wai, A. K. et al. Association of molnupiravir and nirmatrelvir-ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19. Lancet Reg. Health West. Pac. 30, 100602 (2023).","journal-title":"Lancet Reg. Health West. Pac."},{"key":"2126_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s40121-023-00760-x","volume":"12","author":"C Weng","year":"2023","unstructured":"Weng, C. et al. Safety and efficacy of paxlovid against omicron variants of coronavirus disease 2019 in elderly patients. Infect. Dis. Ther. 12, 649\u2013662 (2023).","journal-title":"Infect. Dis. Ther."},{"key":"2126_CR16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/cid\/ciac673","volume":"76","author":"S Ganatra","year":"2023","unstructured":"Ganatra, S. et al. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019. Clin. Infect. Dis. 76, 563\u2013572 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"2126_CR17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2204919","volume":"387","author":"R Arbel","year":"2022","unstructured":"Arbel, R. et al. Nirmatrelvir use and severe covid-19 outcomes during the omicron surge. N. Engl. J. Med. 387, 790\u2013798 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2126_CR18","unstructured":"National Medical Products Administration. Domestically developed drug joins virus battle. http:\/\/english.nmpa.gov.cn\/2022-08\/15\/c_797867.htm (2022)."},{"key":"2126_CR19","unstructured":"National Medical Products Administration. National medical products administration conditionally approved the marketing of Azvudine tablets. https:\/\/www.nmpa.gov.cn\/zhuanti\/cxylqx\/cxypxx\/20210721142223181.html (2021)."},{"key":"2126_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-020-00351-z","volume":"5","author":"B Yu","year":"2020","unstructured":"Yu, B. & Chang, J. Azvudine (FNC): a promising clinical candidate for COVID-19 treatment. Signal Transduct. Target Ther. 5, 236 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2126_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202001435","volume":"7","author":"Z Ren","year":"2020","unstructured":"Ren, Z. et al. A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study. Adv. Sci. 7, e2001435 (2020).","journal-title":"Adv. Sci."},{"key":"2126_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(21)01755-4","volume":"398","author":"L Huang","year":"2021","unstructured":"Huang, L. et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet 398, 747\u2013758 (2021).","journal-title":"Lancet"},{"key":"2126_CR23","doi-asserted-by":"publisher","first-page":"1215916","DOI":"10.3389\/fmed.2023.1215916","volume":"10","author":"SB de Souza","year":"2023","unstructured":"de Souza, S. B. et al. Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients. Front. Med. 10, 1215916 (2023).","journal-title":"Front. Med."},{"key":"2126_CR24","unstructured":"National Health Commission of the People\u2019s Republic of China. COVID-19 diagnosis and treatment plan (trial version 9). https:\/\/www.gov.cn\/zhengce\/zhengceku\/2022-03\/15\/content_5679257.htm (2022)."},{"key":"2126_CR25","unstructured":"National Health Commission of the People\u2019s Republic of China. COVID-19 diagnosis and treatment plan (trial version 10). https:\/\/www.gov.cn\/zhengce\/zhengceku\/2023-01\/06\/content_5735343.htm (2023)."},{"key":"2126_CR26","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1093\/cid\/ciac443","volume":"76","author":"R Najjar-Debbiny","year":"2023","unstructured":"Najjar-Debbiny, R. et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin. Infect. Dis. 76, e342\u2013e349 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"2126_CR27","doi-asserted-by":"publisher","first-page":"e20153","DOI":"10.1016\/j.heliyon.2023.e20153","volume":"9","author":"Z Chen","year":"2023","unstructured":"Chen, Z. & Tian, F. Efficacy and safety of azvudine in patients with COVID-19: a systematic review and meta-analysis. Heliyon 9, e20153 (2023).","journal-title":"Heliyon"},{"key":"2126_CR28","doi-asserted-by":"publisher","first-page":"e28441","DOI":"10.1002\/jmv.28441","volume":"95","author":"B Amani","year":"2023","unstructured":"Amani, B. & Amani, B. Efficacy and safety of nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis. J. Med. Virol. 95, e28441 (2023).","journal-title":"J. Med. Virol."},{"key":"2126_CR29","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1016\/j.apsb.2023.07.007","volume":"13","author":"K Zong","year":"2023","unstructured":"Zong, K. et al. Azvudine reduces the in-hospital mortality of COVID-19 patients: a retrospective cohort study. Acta Pharm. Sin. B. 13, 4655\u20134660 (2023).","journal-title":"Acta Pharm. Sin. B."},{"key":"2126_CR30","doi-asserted-by":"publisher","first-page":"101981","DOI":"10.1016\/j.eclinm.2023.101981","volume":"59","author":"Y Sun","year":"2023","unstructured":"Sun, Y. et al. Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study. EClinicalMedicine 59, 101981 (2023).","journal-title":"EClinicalMedicine"},{"key":"2126_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28947","volume":"95","author":"H Yang","year":"2023","unstructured":"Yang, H. et al. Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: results of a real-world study. J. Med. Virol. 95, e28947 (2023).","journal-title":"J. Med. Virol."},{"key":"2126_CR32","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/j.jinf.2023.05.012","volume":"87","author":"Y Dian","year":"2023","unstructured":"Dian, Y., Meng, Y., Sun, Y., Deng, G. & Zeng, F. Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities. J. Infect. 87, e24\u2013e27 (2023).","journal-title":"J. Infect."},{"key":"2126_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28756","volume":"95","author":"G Deng","year":"2023","unstructured":"Deng, G. et al. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a retrospective cohort study. J. Med. Virol. 95, e28756 (2023).","journal-title":"J. Med. Virol."},{"key":"2126_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08965-8","volume":"24","author":"X Han","year":"2024","unstructured":"Han, X. et al. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study. BMC Infect. Dis. 24, 57 (2024).","journal-title":"BMC Infect. Dis."},{"key":"2126_CR35","doi-asserted-by":"publisher","first-page":"102468","DOI":"10.1016\/j.eclinm.2024.102468","volume":"69","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir\/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study. EClinicalMedicine 69, 102468 (2024).","journal-title":"EClinicalMedicine"},{"key":"2126_CR36","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2107715","volume":"385","author":"A Jara","year":"2021","unstructured":"Jara, A. et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N. Engl. J. Med. 385, 875\u2013884 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2126_CR37","unstructured":"World Health Organization. Therapeutics and COVID\u201019: living guideline. https:\/\/iris.who.int\/handle\/10665\/365584 (2023)."},{"key":"2126_CR38","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s11739-014-1124-1","volume":"9","author":"PM Mannucci","year":"2014","unstructured":"Mannucci, P. M. & Nobili, A. Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Intern. Emerg. Med. 9, 723\u2013734 (2014).","journal-title":"Intern. Emerg. Med."},{"key":"2126_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.livres.2023.07.001","volume":"7","author":"Y Shi","year":"2023","unstructured":"Shi, Y., Wang, M., Wu, L., Li, X. & Liao, Z. An updated review on the mechanisms and management of risk groups. Liver. Res. 7, 207\u2013215 (2023).","journal-title":"Liver. Res."},{"key":"2126_CR40","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1016\/j.apsb.2024.03.032","volume":"14","author":"N Sheng","year":"2024","unstructured":"Sheng, N. et al. Selectively T cell phosphorylation activation of azvudine in the thymus tissue with immune protection effect. Acta Pharm. Sin. B. 14, 3140\u20133154 (2024).","journal-title":"Acta Pharm. Sin. B."},{"key":"2126_CR41","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1021\/acs.jmedchem.0c00940","volume":"63","author":"L Sun","year":"2020","unstructured":"Sun, L. et al. Mechanistic insight into antiretroviral potency of 2\u2019-deoxy-2\u2019-\u03b2-fluoro-4\u2019-azidocytidine (FNC) with a long-lasting effect on HIV-1 prevention. J. Med. Chem. 63, 8554\u20138566 (2020).","journal-title":"J. Med. Chem."},{"key":"2126_CR42","doi-asserted-by":"crossref","unstructured":"Loos, N. H. C., Beijnen, J. H. & Schinkel, A. H. The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism? Int. J. Mol. Sci. 23, 9866 (2022).","DOI":"10.3390\/ijms23179866"},{"key":"2126_CR43","doi-asserted-by":"crossref","unstructured":"Telbisz, \u00c1. et al. Interactions of potential anti-COVID-19 compounds with multispecific ABC and OATP drug transporters. Pharmaceutics. 13, 81 (2021).","DOI":"10.3390\/pharmaceutics13010081"},{"key":"2126_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06277-3","volume":"21","author":"B Zhu","year":"2021","unstructured":"Zhu, B. et al. Correlation between white blood cell count at admission and mortality in COVID-19 patients: a retrospective study. BMC Infect. Dis. 21, 574 (2021).","journal-title":"BMC Infect. Dis."},{"key":"2126_CR45","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ajem.2020.11.058","volume":"40","author":"M Seyit","year":"2021","unstructured":"Seyit, M. et al. Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19. Am. J. Emerg. Med. 40, 110\u2013114 (2021).","journal-title":"Am. J. Emerg. Med."},{"key":"2126_CR46","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11255-022-03348-5","volume":"55","author":"K Schnabel","year":"2023","unstructured":"Schnabel, K. et al. Urinary albumin-to-creatinine ratio and serum albumin are predictors of acute kidney injury in non-ventilated COVID-19 patients: a single-center prospective cohort study. Int. Urol. Nephrol. 55, 711\u2013720 (2023).","journal-title":"Int. Urol. Nephrol."},{"key":"2126_CR47","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.amjms.2022.06.027","volume":"364","author":"Y Miyata","year":"2022","unstructured":"Miyata, Y. et al. Serum cystatin C and CRP are early predictive biomarkers for emergence of hypoxia in COVID-19. Am. J. Med. Sci. 364, 706\u2013713 (2022).","journal-title":"Am. J. Med. Sci."},{"key":"2126_CR48","unstructured":"U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) Version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf (2017)."},{"key":"2126_CR49","doi-asserted-by":"publisher","first-page":"5447","DOI":"10.7150\/jca.35053","volume":"10","author":"L Liu","year":"2019","unstructured":"Liu, L. et al. N6-methyladenosine-related genomic targets are altered in breast cancer tissue and associated with poor survival. J. Cancer 10, 5447\u20135459 (2019).","journal-title":"J. Cancer"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02126-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02126-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02126-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T23:03:27Z","timestamp":1737068607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02126-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2126"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02126-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"11 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"30"}}